
What did the FDA approve Gazyva for on November 13?
The FDA’s first approval specifically for primary membranous nephropathy in adults at risk of progression, based on the MAJESTY trial: complete remission in 36% on Gazyva versus 6% on tacrolimus among 142 adults. Honest limits: the trial did not compare against rituximab, later duration and eGFR endpoints were not formally tested, and dosing and price were not in the FDA notice.
Short answer: on November 13, the FDA approved Gazyva for primary membranous nephropathy — a kidney condition where the immune system attacks the kidney’s filters — in adults whose disease is at risk of progressing. It is the first FDA approval written specifically for this condition.Why it matters: until now, treatment for primary membranous nephropathy has leaned on medicines approved for other uses. A purpose-built approval gives kidney specialists a labelled option with trial data behind it for patients whose protein loss and kidney function are heading the wrong way.What the trial showed: in the MAJESTY trial of 142 adults, complete remission was reached by 36% of people on Gazyva compared with 6% on tacrolimus, the comparison treatment used in the study.What the trial did not show — read this part carefully: MAJESTY did not compare Gazyva against rituximab, the treatment guidelines often prefer, so we cannot say from this trial which of the two works better.
Some later endpoints, including how long remission lasts and the kidney-function (eGFR) measures, were not formally tested after the trial’s testing hierarchy stopped. And the FDA notice did not include dosing or price, so cost questions cannot be answered yet.Pro tip: if you or a family member has membranous nephropathy, the useful question for your nephrologist is not ‘is this the best drug?’ but ‘how does this approval change my options, given what I have already tried?’ Early and factual is the right way to hold this news — a real step, with real gaps still to fill.
Ask AI about this tip
Send this tip to your favorite AI assistant for a plain-language walkthrough, follow-up questions, or help applying it to your device.